Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

128.85 -0.53 (-0.41%)
Official Closing Price Updated: 7:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
44 45 Next >
Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor
From Tandem Diabetes Care, Inc.
Via Business Wire
Beyond The Numbers: 5 Analysts Discuss Abbott Laboratories Stock
Via Benzinga
Could Abbott Laboratories Stock Help You Become a Millionaire?
There is a lot going the company's way, despite recent struggles. 
Via The Motley Fool
3 Top Dividend Growth Stocks to Buy in 2024
Income investors should love these great stocks. 
Via The Motley Fool
Where Abbott Laboratories Stands With Analysts
Via Benzinga
$1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Peering Into Abbott Laboratories's Recent Short Interest
Via Benzinga
Eli Lilly, Johnson & Johnson And Other Health Care Stocks From Wall Street's Most Accurate Analysts
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes... 
Via Benzinga
Silver Economy Successes: 3 Stocks Benefitting From an Aging Population
Explore our in-depth analysis of aging population stocks, uncovering the opportunities and challenges in this sector. 
Via InvestorPlace
Topics Economy
Exposures Economy
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Via Benzinga
5 Top Stocks to Buy With Your End-of-the-Year Bonus
Your bonus could become the gift that keeps on giving. 
Via The Motley Fool
Better Growth Stock: AbbVie vs. Abbott Laboratories
Do Humira's declining sales give Abbott Laboratories the edge as the better growth stock? 
Via The Motley Fool
Spotlight on Abbott Laboratories: Analyzing the Surge in Options Activity
Via Benzinga
Dividend Income Update For November 2023
It’s dividend income update time. This is one of my favorite times of the month, as I get to review the previous month of passive income received from my dividend income portfolio. 
Via Talk Markets
3 No-Brainer Healthcare Stocks to Buy Right Now
These players have what it takes to boost your portfolio over time. 
Via The Motley Fool
AbbVie continues shopping spree with biotech buyout
While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend. 
Via MarketBeat
2 Healthcare Stocks to Buy Hand Over Fist in December
These stocks are great options now -- and most any month. 
Via The Motley Fool
Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.
These particular players look cheap right now. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Via Benzinga
Jim Cramer: Buy This Financial Stock, 'I Think They're High Quality'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vishay Intertechnology, Inc. 
Via Benzinga
Medtronic: oversold, overextended high yield reversal in play
The reversal in Medtronic has been brewing for some time but is gaining traction after strong second quarter earnings that came with improved guidance 
Via MarketBeat
Exposures COVID-19
Magnificent 7 Take Center Stage In Hedge Fund Portfolios: Analysts Warn Of Extreme Concentration
Hedge fund portfolios are intensifying their focus on technology stocks, with holdings in mega-cap tech reaching record levels. 
Via Benzinga
Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.
New medicines for weight loss and diabetes stand to disrupt the competitive scene. 
Via The Motley Fool
Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029
EQNX::TICKER_START (OTCPK:CNER),(NASDAQ:PODD),(NASDAQ:TNDM),(NYSE:LLY),(NYSE:ABT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
3 Dividend Giants to Grow Wealth no Matter What the Market Is Doing
You'll be happy to own these top companies in any market environment. 
Via The Motley Fool
Novo Nordisk, Eli Lilly Skid — But These Weight-Loss Results Are 'Hard To Ignore'
Patients who took Wegovy for five years had a 70% reduced risk of developing diabetes. 
Via Investor's Business Daily
2 No-Brainer Stocks to Buy for Forever Dividend Growth
These companies generate billions of dollars in free cash flow every year. 
Via The Motley Fool
2 Medical Device Companies Experiencing Strong Demand Even as Weight-Loss Drugs Rise in Popularity
Investors could be making a mistake by selling off these stocks this year. 
Via The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Dividend Kings to Buy for Royal Returns
Unlock the secrets of dividend kings, the aristocrats of the stock market with unparalleled records of raising dividends yearly. 
Via InvestorPlace
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
44 45 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.